Gastric Cancer:

Sirexatamab (DKN-01) in gastric cancer

The expression of DKK1 is associated with shorter overall survival in gastric cancer patients and with shorter time to treatment progression on current therapies. Sirexatamab (DKN-01) has demonstrated significant tumor reductions in preclinical models and in clinical trials as a monotherapy and in combination with anti-PD-1 antibody immune checkpoint inhibitors and with chemotherapy.

• DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B
• DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish
• DisTinGuish: Tislelizumab combination: ASCO 2023 poster
• DisTinGuish: Tislelizumab combination: SITC 2022 poster
• DisTinGuish: Tislelizumab combination: ESMO 2022 poster
• WaKING: Atezolizumab combination: ESMO 2022 poster
• DisTinGuish: ASCO GI 2022 poster
• DisTinGuish: Tislelizumab combination: ESMO 2021 poster
• P102 Keytruda Combination Manuscript: Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers
• P102 Keytruda PD-1 Experienced Patients: SITC 2020
• P102 Keytruda Combination PD-1 Naïve Patients: ASCO GI 2020
• Paclitaxel combination: AACR 2018